key: cord-0758813-k2oth5is authors: De Greef, Julien; Scohy, Anaïs; Zech, Francis; Aboubakar, Frank; Pilette, Charles; Gerard, Ludovic; Pothen, Lucie; Yildiz, Halil; Belkhir, Leïla; Yombi, Jean Cyr title: Determinants of IgG antibodies kinetics after severe and critical COVID‐19 date: 2021-05-12 journal: J Med Virol DOI: 10.1002/jmv.27059 sha: 638d006c71e0e1029839f5f9a3ee9e577c56fec4 doc_id: 758813 cord_uid: k2oth5is The kinetics of IgG antibodies after coronavirus disease 2019 (COVID‐19) remain poorly understood. We investigated factors influencing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) IgG antibody levels and time to seronegativation during the follow‐up of severe and critically ill patients. We retrospectively reviewed serological evaluations drawn during the follow‐up of severe or critical laboratory‐proven COVID‐19 patients hospitalized at a large academic hospital. Specific IgG titers were measured using a chemiluminescent assay targeting anti‐spike and anti‐nucleocapsid protein IgG. The influence of time, demographic factors, clinical and paraclinical characteristics, and COVID‐19 therapeutics on IgG levels were assessed through linear regression using a mixed‐effect model, and delay until IgG negativation through a Weibull regression model. The cohort included 116 patients with a total of 154 IgG measurements drawn at a median of 79 days after diagnosis. IgG antibodies were increased with age (p = 0.005) and decreased significantly over time (p = 0.0002). Using elapsed time and age as covariates, we demonstrated higher IgG levels in patients with a higher body mass index (BMI) (p = 0.0026) and lower IgG levels in immunocompromised patients (p = 0.032). A high BMI was further found to delay and immunodeficiency to hasten significantly seronegativation, whereas no significant effect was observed with corticosteroids. These data highlight the waning over time of IgG antibodies after severe or critical COVID‐19. Age, BMI, and immunosuppression also appear to influence the IgG kinetics, while short‐term corticotherapy does not. Those data improve the understanding of SARS‐CoV‐2 serology while further research should determine the determinants of long‐term seroprotection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a major human pathogen. Coronavirus disease 2019 caused by SARS-CoV-2 is primarily diagnosed through real-time reverse-transcription polymerase chain reaction (RT-PCR) testing. 1 Numerous serological tests have been developed and commercialized, relying mostly on enzyme-linked immunosorbent assay (ELISA) and chemiluminescence assays (CLIA) to detect IgA, IgM, or IgG against SARS-CoV-2 antigens (spike and nucleocapsid glycoproteins). The detection of antibodies can be used as a diagnostic tool at later timepoints in the disease course, when the sensitivity of RT-PCR decreases. 2 As IgG antibodies are expected to remain detectable after infection resolution, 3 serological testing is also used in seroprevalence studies, to diagnose past exposure to SARS-CoV-2, including in pauci or asymptomatic patients 4 although it has been stressed that the magnitude of the antibody response appears to be associated with disease severity. 5 Serological testing also carries the theoretical possibility to inform individuals about their immune protection against reinfections. Indeed, the presence of detectable antibodies after COVID-19 has been shown to correlate with immune protection for at least 6 months in a large cohort of healthcare workers. 6 However, antibody kinetics remains incompletely understood. While most patients elicit a robust humoral response with detectable anti-SARS-CoV-2 antibodies, those antibodies will quickly become indetectable in a significant subset of patients. 7, 8 Factors influencing the persistence of high antibody titers following COVID-19 remain poorly identified. In addition, whether treatment of COVID-19 with immunosuppressive agents such as dexamethasone influences antibody levels and kinetic has not been assessed. This study aims (i) to describe the kinetics of serum IgG antibodies and (ii) to investigate the determinants underlying kinetics and IgG negativation at the convalescent phase of COVID-19 in a cohort of hospitalized patients with severe and/or critical disease. Patients with RT-PCR-proven COVID-19 and who reached at least four on the WHO ordinal scale (i.e., patients requiring oxygen supplementation) were identified within our database of COVID-19 patients hospitalized in Cliniques universitaires Saint-Luc, an academic hospital of 1000 beds in Brussels, Belgium. We further selected for analysis the patients with at least one serological assessment drawn after the 14th day of diagnosis and before November 5, the date of analysis. We excluded patients who received convalescent plasma therapy. All patients were treated according to Belgian and local guidelines. Besides best supportive care, and in accordance with ongoing Belgian guidelines at that time, 9 most patients were treated with hydroxychloroquine until the end of May 2020. Although not recommended before the publication of Recovery trial results, 10 corticosteroids had been used earlier by some clinicians in case of progressing respiratory failure. The following data were studied: demographics, clinical characteristics (signs and symptoms, comorbidities, and usual treatment), biological and imaging results, treatments administered, and outcome. The local ethics committee approved our database (registration number 2020/06AVR/201) and waived the requirement for informed consent based on the retrospective observational design of the study. With the aim of providing the most objective assessment of disease onset, the date of diagnosis was defined as the date of the first positive SARS-CoV-2 RT-PCR. Immunosuppression was defined as any condition or treatment known to interfere with humoral or cellular immunity. Before running statistical analysis, we decided not to consider as immunosuppressed two HIV-positive patients with high CD4 cells count (650 and 1120 cells/mm 3 , respectively) and long-term viral replication control. The detection of SARS-CoV-2 antibodies in human serum was performed using the MAGLUMI-800 CLIA system (Snibe Diagnostic). This system allows the detection of both IgM and IgG binding SARS-CoV-2 spike and nucleocapsid proteins. MAGLUMI assay has received CE marking and Food and Drug Administration's Emergency Use Authorization. According to the manufacturer, the calculated sensitivities and specificities of IgG were respectively 91.2% and 97.3%. This high sensitivity was recently confirmed by Soleimani et al. 11 who reported a sensitivity of more than 95% by the 18th day after symptom onset. A result was considered positive if the index is more than or equal to 1.00 AU/ml, according to the manufacturer's recommendations. Results are presented as means ± SD or median (interquartile range We studied the delay until IgG negativation using a Weibull regression model; when the last available IgG measurement remained positive, this test date was considered as a censor; when the first available test was already negative, we assumed that the last positive date was Day 21. Hazard ratios (HR) were calculated with age as a covariate. To minimize the bias related to the asymmetry of the independent variables, we used a sandwich-variance for regressions and calculated degrees of freedom according to Bell and McCaffrey. 12 All p values were two-sided and p values ≤ 0.05 were considered significant. Statistical analyses were performed using SPSS v27 (IBM). We included a total of 154 IgG measurements performed on 116 patients ( Figure 1 ). The main baseline characteristics of our cohort are shown in Table 1 The distribution of IgG titers over time is further described with medians and CI in Figure S1 . We found a trend towards an increase of IgG with increased age in univariate analysis (p = 0.077), which became significant (p = 0.005) when considering time elapsed between diagnosis and IgG measurements as a covariate. We found increasing IgG titers with higher BMI (p = 0.012 and 0.0026, respectively for Model 1 and 2) and lower IgG levels in the group of immunocompromised patients (two patients with hypogammaglobulinemia excluded) (p = 0.063 and 0.032, respectively for Model 1 and 2). We found We did not find association between symptoms presented by the patients at admission and the IgG titers, with the exception of cough (p value respectively 0.078 and 0.035 for Model 1 and 2). Laboratory tests on admission known as associated with unfavorable outcome such as C-reactive protein, lactate dehydrogenase, creatinine, or low lymphocyte count did not show any influence on IgG levels (Model 1 and 2), with the exception of liver function test upon admission: high aspartate aminotransferase (ASAT) levels were significantly associated with higher IgG titers (p = 0.047 and 0.036) while the association was not significant for alanine aminotransferase (Table S1 ). Concerning the severity of infection, the extent of lung involvement on the admission computed tomography scan showed no significant association with IgG levels. Moreover, we did not find an association between the severity of in- We did not find the influence of the administration of corticosteroids as COVID-19 treatment on IgG titers (p = 0.12 and 0.072) using both models. Those results were confirmed after weighting with a propensity score for the use of corticosteroids (Table 2 ). We further assessed the association between the different variables and the occurrence of IgG seronegativity during follow-up. Age was not shown to affect the time to seronegativation (p = 0.34). A higher BMI (HR = 0.843; p = 0.020) and the presence of cough (HR = 0.203; p = 0.026) were associated with delayed seronegativation. On the opposite, immunodeficiency was found significantly associated with shorter time to seronegativation (HR = 6.170; p = 0.0042). Other comorbidities and severity of infection (assessed by the need for HFNC, MV, or either respiratory support) showed no significant effect. No patient treated with corticosteroids was found seronegative at follow-up. All results were confirmed in a bivariate analysis using age as a covariate (Table 3 ). In this study, we retrospectively analyzed IgG titers drawn during the follow-up of severe and critical COVID-19 patients. We found a significant decrease of IgG titers over time. We showed a negative linked to a decreased naïve B cell repertoire. 24 Illustrating this reduced B-cell responsiveness, overall lower IgG levels after vaccination have been demonstrated in elderlies. 25 Moreover, a decreased antibody quality in old age has also been shown. 26 The impact of obesity on humoral immunity appears more complex. A reduced level of immunoglobulin levels after hepatitis B and tetanus vaccination has been shown in this population, 27 but Sheridan et al. 28 found a significant correlation between BMI and IgG levels one month after influenza vaccination, but a greater decline at 12 months in obese patients. Further follow-up of the obese COVID-19 patient population is warranted to draw a better picture of long-term immunoglobulin kinetics. In their seroprevalence study of the Icelandic population, Gudbjartsson et al. 4 found an association in recovered persons between higher antibody levels and older age, a higher BMI, but also disease severity. The latter finding corroborates other results showing that levels of anti-SARS-CoV-2 antibodies correlate with disease severity. 23, 29 As age and obesity constitute major risk factors for severe COVID-19 and its dysregulated immune response, 30 higher antibody levels at follow-up might mirror the intensity of the immune response during infection. Interestingly, we also showed higher IgG titers in patients with elevated ASAT at admission, a feature that has been associated to COVID-19 severity. 31 One might argue that our analysis did not show any correlation between IgG levels and infection severity. However, one should keep in mind that our analysis focused on hospitalized patient with severe COVID-19, thus limiting its ability to detect an effect when considering severity as a spectrum ranging from asymptomatic to critical disease. This ability was further decreased by the fact that we could not include the sickest patients in our analysis, as death at the acute stage of infection precluded the drawing of follow-up blood samples. The usefulness and yield of serological evaluation in immunocompromised patients remain unknown. Small case series 32, 33 have found seroconversion of transplant recipients but reduced seroconversion has been shown in hematological malignancy patients. 34 We found no correlation between the administration of corticosteroids as COVID-19 treatment and IgG titers. In the context of SARS-CoV-1, Woo et al. 36 Short-course corticosteroid treatments have been shown to induce IgG as well as IgA level depression that may persist for several weeks. 38 More worryingly, a decreased neutralizing antibody response to naturally acquired herpes virus infection has been shown on volunteers exposed to short-term corticosteroids. However, in line with our findings, antibody response to antigens appeared unaffected. 39 Although limited by its sample size, our data provide The first limitation of this study is its retrospective design. Data were retrieved from electronic health records, and incomplete data reporting cannot be excluded, particularly regarding the reported symptoms, as other collected data are by nature less prone to errors. The second limitation is that we did not assess the neutralizing activity of included serums. Valvidia et al. 40 Lastly, the possibility of reexposure to SARS-CoV-2 during follow-up cannot be excluded. However, all but four long-term serological assessments had been drawn before October, when the second COVID-19 wave started in Belgium. In summary, we measured specific IgG antibodies after severe or critical COVID-19 and found that time and immunodeficiency are associated with reduced IgG levels at followup, while age and BMI were associated to increased levels. Corticosteroids given as short-term treatment for COVID-19 did not show influence, and BMI and immunodepression were respectively associated with decreased and increased rates of seronegativation. The authors declare that there are no conflict of interests. All authors approved the final draft of the manuscript. The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.27059 The anonymized data that support the findings of this study are available from the corresponding author upon reasonable request. Julien De Greef http://orcid.org/0000-0003-0200-1237 Halil Yildiz http://orcid.org/0000-0003-3103-1638 Leïla Belkhir https://orcid.org/0000-0002-1701-7584 Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays Duration of humoral immunity to common viral and vaccine antigens Humoral immune response to SARS-CoV-2 in Iceland Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Antibodies to SARS-CoV-2 are associated with protection against reinfection Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants Dexamethasone in Hospitalized Patients with COVID-19 -Preliminary Report Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients Bias reduction in standard errors for linear regression with multi-stage samples Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19 The time course of the immune response to experimental coronavirus infection of man Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients Viral and antibody kinetics of COVID-19 Patients With Different Disease Severities In Acute And Convalescent Phases: A 6-month Follow-up Study The impact of obesity on the immune response to infection The twilight of immunity: emerging concepts in aging of the immune system The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response Sex differences in the decline of neutralizing antibodies to SARS-CoV-2 Temporal antibody responses to SARS-CoV-2 in patients of coronavirus disease 2019 A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence Antibody response to influenza vaccination in the elderly: a quantitative review Antibody quality in old age Impaired immunogenicity of hepatitis B vaccine in obese persons Obesity is associated with impaired immune response to influenza vaccination in humans Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019 Factors associated with COVID-19-related death using OpenSAFELY Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study Influence of immunosuppression on seroconversion against SARS-CoV-2 in two kidney transplant recipients Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: a case series from the United States Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus Immune regulation by glucocorticoids The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels Corticosteroids and immunoglobulin synthesis Inference of SARS-CoV-2 spikebinding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG Immunological memory to SARS-CoV-2 assessed for greater than six months after infection Early high-titer plasma therapy to prevent severe COVID-19 in older adults SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article Determinants of IgG antibodies kinetics after severe and critical COVID-19